Nanoparticles as drug delivery systems in cancer medicine: Emphasis on RNAi-containing nanoliposomes

131Citations
Citations of this article
237Readers
Mendeley users who have this article in their library.

Abstract

Nanomedicine is a growing research field dealing with the creation and manipulation of materials at a nanometer scale for the better treatment, diagnosis and imaging of diseases. In cancer medicine, the use of nanoparticles as drug delivery systems has advanced the bioavailability, in vivo stability, intestinal absorption, solubility, sustained and targeted delivery, and therapeutic effectiveness of several anticancer agents. The expansion of novel nanoparticles for drug delivery is an exciting and challenging research filed, in particular for the delivery of emerging cancer therapies, including small interference RNA (siRNA) and microRNA (miRNAs)-based molecules. In this review, we focus on the currently available drug delivery systems for anticancer agents. In addition, we will discuss the promising use of nanoparticles for novel cancer treatment strategies. © 2013 by the authors; licensee MDPI, Basel, Switzerland.

Cite

CITATION STYLE

APA

Díaz, M. R., & Vivas-Mejia, P. E. (2013, November 4). Nanoparticles as drug delivery systems in cancer medicine: Emphasis on RNAi-containing nanoliposomes. Pharmaceuticals. MDPI AG. https://doi.org/10.3390/ph6111361

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free